GSK

Ouroboros Medicines is a biotechnology company that specializes in immunology and focuses on treating long-term immune-mediated illnesses. The company addresses chronic immune-mediated conditions directly by integrating scientific knowledge, a proven history of progressing cell-depleting treatments through clinical trials, and a strong pipeline.

Elegen is a biotechnology company founded in 2017, focused on developing microfluidic technology to advance synthetic biology. Led by Dr. Matthew Hill, Elegen aims to revolutionize the field by engineering entire genomes and creating innovative DNA synthesizers. Their technology is designed to enhance the speed and efficiency of DNA sequence testing, thereby facilitating significant progress in biomedical research and healthcare applications. Through these efforts, Elegen seeks to contribute to the rapid development of solutions that address various challenges in the life sciences sector.

BioVersys AG is a biopharmaceutical company based in Basel that specializes in the research and development of innovative drugs aimed at overcoming drug resistance in bacterial pathogens. The company is dedicated to addressing the pressing global health challenge of multidrug-resistant bacterial infections by restoring the effectiveness of existing antibiotics. BioVersys utilizes its proprietary TRIC (Transcriptional Regulator Inhibitory Compounds) technology platform to discover new therapies that inhibit bacterial resistance mechanisms. This approach not only targets novel bacterial pathways but also provides healthcare professionals with new treatment options for patients suffering from life-threatening infections caused by resistant bacterial strains.

Sitryx Therapeutics is a biopharmaceutical company founded in 2018 and headquartered in Oxford, United Kingdom. The company focuses on developing innovative disease-modifying therapeutics in the fields of immuno-oncology and immuno-inflammation by regulating cell metabolism. Sitryx aims to enhance immune cell functions to inhibit tumor growth and improve immune responses. Co-founded by leading scientists from the United States and Europe, the company has attracted significant investment, including $30 million in Series A funding from a consortium of specialist investors. Sitryx has established a diverse pipeline of projects at various stages of drug discovery, positioning itself at the forefront of immunometabolism research.

Patientory, Inc. is a healthcare technology company based in Atlanta, Georgia, established in 2015. It offers a health data management platform that enables individuals to securely store, manage, and share their health information. The platform empowers patients to take control of their medical records and chronic illness management while facilitating better communication and support between healthcare providers and patients. By integrating a blockchain-enabled network, Patientory streamlines access to health data, enhances care coordination, and provides insights into health outcomes. This approach aims to democratize health data ownership, reduce healthcare costs, and improve overall patient engagement and health management.

Sitryx Therapeutics is a biopharmaceutical company founded in 2018 and headquartered in Oxford, United Kingdom. The company focuses on developing innovative disease-modifying therapeutics in the fields of immuno-oncology and immuno-inflammation by regulating cell metabolism. Sitryx aims to enhance immune cell functions to inhibit tumor growth and improve immune responses. Co-founded by leading scientists from the United States and Europe, the company has attracted significant investment, including $30 million in Series A funding from a consortium of specialist investors. Sitryx has established a diverse pipeline of projects at various stages of drug discovery, positioning itself at the forefront of immunometabolism research.

Calporta is developing selective small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for the treatment of Niemann-Pick C Disease (NPC) and other lysosomal storage diseases. Mutations that cause NPC lead to impaired intracellular lipid trafficking and lead to lysosomal accumulation of cholesterol and biolipds. TRPML1 is an ion channel in the lysosome and a key regulator of lysosomal trafficking processes. Impaired TRPML1 function has been implicated in multiple pathological conditions, including NPC. Agonists of TRPML1 restore calcium efflux and normalize lysosomal trafficking and function. In addition to NPC and other lysosomal storage diseases, agonists of TRPML1 may have broad potential in other diseases such as muscular dystrophy and various taopathies such as Alzheimer's disease. Calporta's approach is based on research from the lab of Haoxing Xu, Ph.D., at the University of Michigan.

Cadherx Therapeutics develops therapeutic antibodies targeting soluble E-cadherin.

Thrasos is a bio-therapeutics company dedicated to discovering and developing targeted therapies for severe organ failure, with a primary emphasis on kidney diseases. The company's lead program, THR-184, aims to prevent and treat acute kidney injury (AKI). Additionally, Thrasos is advancing a preclinical development program that addresses chronic kidney disease (CKD). The company also focuses on developing innovative treatments for rare kidney-related conditions, such as myeloma cast nephropathy, which occurs when protein aggregates obstruct renal tubules, leading to the risk of permanent kidney damage. Through its efforts, Thrasos seeks to provide timely and effective treatment options for patients suffering from these serious kidney issues.

SpringLeaf Therapeutics (formerly known as Entra Pharmaceuticals, Inc.) is creating innovative therapeutic modalities to address serious disease and elevate the quality of care for patients. SpringLeaf's technology is based on convergent science and is designed to enable and differentiate therapeutics. SpringLeaf was founded based on breakthrough science at MIT and is backed by leading investors including Flybridge Capital Partners and North Bridge Venture Partners.

Anacor Pharmaceuticals is a biopharmaceutical company that specializes in discovering, developing, and commercializing small-molecule therapeutics based on its boron chemistry platform. The company is known for its marketed product, KERYDIN, a topical solution for treating onychomycosis of the toenails. Its lead candidate, crisaborole topical ointment, is currently in Phase III clinical trials aimed at addressing mild-to-moderate atopic dermatitis and psoriasis. Additionally, Anacor is developing AN3365, an antibiotic for infections caused by Gram-negative bacteria. The company has established collaboration agreements with various organizations to explore new treatments for diseases such as African trypanosomiasis, tuberculosis, and Chagas disease. Anacor Pharmaceuticals, which was incorporated in 2000 and is headquartered in Palo Alto, California, previously operated under the name AnaMax, Inc. It has been a subsidiary of Pfizer since June 2016.

diaDexus is a privately held biotechnology company based in the United States, specializing in the discovery, development, and commercialization of diagnostic products. The company is known for its lead product, the PLAC Test, which measures Lp-PLA2, an enzyme linked to vascular inflammation and critical in assessing the risk of coronary heart disease and ischemic stroke associated with atherosclerosis. This test is notable for being the only FDA-cleared blood test designed to aid in risk assessment for these cardiovascular conditions. In addition to the PLAC Test, diaDexus develops a range of diagnostic test kits for various health conditions, including liver disease, cancer markers, renal disease, diabetes, and electrolyte imbalances. The company primarily operates in the United States, with additional presence in Europe and other regions, contributing to its overall revenue.

Anacor Pharmaceuticals is a biopharmaceutical company that specializes in discovering, developing, and commercializing small-molecule therapeutics based on its boron chemistry platform. The company is known for its marketed product, KERYDIN, a topical solution for treating onychomycosis of the toenails. Its lead candidate, crisaborole topical ointment, is currently in Phase III clinical trials aimed at addressing mild-to-moderate atopic dermatitis and psoriasis. Additionally, Anacor is developing AN3365, an antibiotic for infections caused by Gram-negative bacteria. The company has established collaboration agreements with various organizations to explore new treatments for diseases such as African trypanosomiasis, tuberculosis, and Chagas disease. Anacor Pharmaceuticals, which was incorporated in 2000 and is headquartered in Palo Alto, California, previously operated under the name AnaMax, Inc. It has been a subsidiary of Pfizer since June 2016.

Concert Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drugs for autoimmune and central nervous system disorders. The company employs an innovative precision deuterium chemistry platform to enhance the properties of established drug molecules, which enables the creation of new chemical entities with potential efficacy and safety advantages. Notable product candidates include CTP-543, currently in Phase III trials for alopecia areata, CTP-692 for schizophrenia in Phase II trials, and AVP-786, which targets neurological and psychiatric disorders in Phase III trials. Concert Pharmaceuticals also engages in strategic collaborations with various pharmaceutical companies to support its development efforts. Founded in 2006 and based in Lexington, Massachusetts, the company aims to streamline research and development processes, reducing associated risks and costs while advancing its therapeutic pipeline.

It is a joint venture company

CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in the field, the company focuses on the specific inhibition of calcium release-activated calcium channels. This innovative approach seeks to modulate the immune response and protect against tissue cell injury, addressing significant unmet medical needs in life-threatening inflammatory conditions for which existing therapies are lacking. CalciMedica's proprietary technology has the potential to offer therapeutic benefits in these challenging areas of healthcare.

diaDexus is a privately held biotechnology company based in the United States, specializing in the discovery, development, and commercialization of diagnostic products. The company is known for its lead product, the PLAC Test, which measures Lp-PLA2, an enzyme linked to vascular inflammation and critical in assessing the risk of coronary heart disease and ischemic stroke associated with atherosclerosis. This test is notable for being the only FDA-cleared blood test designed to aid in risk assessment for these cardiovascular conditions. In addition to the PLAC Test, diaDexus develops a range of diagnostic test kits for various health conditions, including liver disease, cancer markers, renal disease, diabetes, and electrolyte imbalances. The company primarily operates in the United States, with additional presence in Europe and other regions, contributing to its overall revenue.

Resistentia Pharmaceuticals, a biopharmaceutical company, develops immunotherapeutic products for allergic asthma and inflammatory disorders. It provides Immunoglobulin E for allergic reactions, including asthma, rhinitis, and dermatitis; and C5a for the treatment of inflammatory conditions, such as rheumatoid arthritis, asthma, and multiple sclerosis. Resistentia Pharmaceuticals AB was founded in 1998 and is based in Uppsala, Sweden.

Trinity Biosystems, Inc. engages in the development and formulation of oral therapeutic proteins. It involves in developing vaccines in the areas of respiratory, digestive, and sexually transmitted diseases, as well as transporting proteins, peptides, and other macromolecules. The company was founded in 2002 and is based in Menlo Park, California.